INTO LONDON MDX STREET LLP

UEA researchers developed a model using Latent Process Decomposition to identify 3 osteosarcoma subtypes, potentially improving clinical trials and treatment by matching treatments to genetic profiles, and identified 8 dysregulated genes as biomarkers.

The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.

Researchers identified three osteosarcoma subtypes using advanced mathematical modelling and machine learning, potentially transforming clinical trials and patient care. This could lead to targeted treatments specific to cancer subtype, moving away from standard chemotherapy.

Filgotinib, an oral JAK inhibitor, met only one of four primary endpoints in a phase III Crohn's disease trial, possibly due to study design issues. Clinical remission was achieved by more patients previously treated with biologics, but endoscopic response was not met. Maintenance phase showed better results, with clinical and endoscopic remission rates improving. Study limitations included early endoscopic assessment and high placebo response rates.